Decreto Rettore Università di Roma "La Sapienza" n. 1267/2020 del 12.05.2020.
Procedura selettiva di chiamata per n.1 posto di Ricercatore a tempo determinato di Tipologia B presso il Dipartimento di Medicina Molecolare - Facoltà di Farmacia e Medicina - Settore concorsuale: 06/A2 - Patologia generale e Patologia clinica - Settore Scientifico Disciplinare: MED/04 – Patologia Generale. Codice Concorso 2020RTDB003.

Rocco Palermo

Curriculum Vitae ai fini della pubblicazione

Rome, 15/06/2020

Part I – General Information

Full Name	Rocco Palermo

Part II – Education

Type	Year	Institution	
University graduation	2003	"Sapienza" University of Rome, Rome, Italy.	Graduation in Biological Sciences. (Bachelor and Master degrees). Thesis title: Ruolo del fattore a/eIF2 nell'inizio della sintesi proteica archeobatterica: analisi funzionale della subunità gamma.
Licensure	2003	University of Tuscia, Viterbo, Italy.	Professional qualification in Biologist.
PhD	2007	University of L'Aquila, L'Aquila, Italy.	PhD in Biotechnology. Thesis title: Il pre-TCR regola l'attivazione di NF-kB Notch3-dipendente nello sviluppo delle cellule T e nell'insorgenza leucemica.
National Qualification	2019	Italian Ministry of Education, University and Research (MIUR) -ANVUR.	Abilitazione Scientifica Nazionale alle funzioni di professore di II fascia SC 06/A2 - Patologia Generale e Patologia Clinica.

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2018	Present	Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.	Assistant Professor (RTDA – SC 06/A2 - SSD MED/04).
2019	Present	Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.	Board Member of the Faculty of the PhD program in Molecular Medicine [code: DOT1326HDK].

IIIB – Other Appointments

Start	End	Institution	Position
2006	2009	Department of Experimental Medicine and Pathology, "Sapienza" University of Rome, Rome, Italy.	Research collaborator (co.co.co.)
2009	2011	Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy.	Postdoctoral Fellow
2011	2012	Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.	Research assistant (Assegnista di ricerca)
2012	2018	Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy.	Post-Doc

Part IV – Teaching experience

Year	Institution	Course
2012	"Sapienza" University of Rome, Rome, Italy.	Technical-practical course for Italian and European PhD students within the workshop: "NotchIT - Proteomics in Notch signaling"
2018 - Present	"Sapienza" University of Rome, Rome, Italy.	"General and Molecular Pathology with Medical Terminology" (code:1038200) for Master's Degree program in Pharmaceutical Chemistry and Technology LM-13.
2019 - Present	"Sapienza" University of Rome, Rome, Italy.	"Pathology and Pathophysiology" (as part of the integrated course of Physiopathologic Bases of Diseases - code: 10589388) for Bachelor's Degree program in Nursing.

Part V - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2008-2011	Dissection of Notch-dependent pathways involved in development of T cell leukemia: insights from mouse models. (Role: **I**)	Investigator Grant AIRC 2008, code: IG5432.	360.000 €
2009-2012	Notch signaling in development and pathology. (Role: **I**)	European Commission FP7 program, code: NotchIT-PITN GA-2008-215761.	716.307 €
2012-2013	Studio di fattibilità mirato a dimostrare il possibile ruolo di modificazioni post-traduzionali a carico della proteina Notch3 (N3) nello sviluppo e/o nella progressione della Leucemia Linfoblastica Acuta a cellule T (T-ALL). (Role: **I**)	Ricerca Scientifica FARI, "Sapienza" University code: C26I12HTKL.	6.500 €
2012-2015	Molecular dissection of Notch3 signaling in T Cell Leukemia: novel mechanistic insights. (Role: **I**)	Investigator Grant AIRC 2012, code: IG13314.	360.000 €
2018	Study of the molecular mechanisms sustaining Notch3 expression in T-cell Acute Lymphoblastic Leukemia. (Role: **PI**)	University Scientific Research funding "Sapienza" University, code: RP11816427E6999A.	3.000 €

2019	Targeting Notch3-driven cancers by means of novel Notch3 receptor intercepting molecules. (Role: **PI**)	University Scientific Research funding " Sapienza" University, code: RM11916B7960D124.	34.527 €
2019	Development of natural and synthetic compounds as kinases inhibitors targeting cancer cells and cancer stem cells. (Role: **Responsabile di unità di ricerca**)	Italian Ministry of Education, University and Research (MIUR) - PRIN - BANDO 2017 code: 2017E84AA4.	70.000 €

Part VI – Research Activities

Keywords	Brief Description
Cancer; Drug discovery; Notch signaling;	Dr. Palermo's research activity is focused on molecular biology of cancer and on the field of drug discovery. In particular, it is centered on the study of the role of Notch signaling and its regulatory pathways in tumorigenesis and resistance to conventional cancer treatment. Notch is a cell-cell communication signaling pathway influencing the key aspects of physiological cellular behavior and it is often deregulated in some diseases including tumors. Therefore, providing a way to modulate Notch activity could have a great potential value in several areas of medicine providing novel therapeutic opportunities for Notch signaling-dependent diseases.
Notch3; NF-kB; pre-TCR; Tal-1;	***2003-2006.*** At the beginning of his career, as a PhD student in Biotechnology at the University of L'Aquila, Dr. Palermo interest has been mostly directed to investigate the crosstalk between Notch and other oncogenic pathways in T-cell Acute Lymphoblastic Leukemia (T-ALL). In this regard, his studies conducted in this period helped to unveil the relevance of the interplay between Notch3 and pre-TCR regulating NF-kB and Tal-1 signaling and the expression of distinct downstream key genes in T-ALL.
Leukemia; T-ALL; HDAC inhibitors; E3 ligase; c-CBL;	***2006 – 2011.*** Subsequently, Dr Palermo joined the Department of Experimental Medicine of "Sapienza" University of Rome, where, firstly as a Research collaborator and then as a Post-doctoral fellow, focused his research on the post-translational modifications of Notch receptor that regulate the strength and the oncogenic activity of the signaling. With regard to this aspect, his work revealed for the first time that acetylation primes Notch3 proteasome-mediated degradation and that deacetylase inhibition favors Notch3 hyper-acetylation/degradation and prevents leukemic cell growth in a T-ALL murine model. In the meantime, Dr Palermo conducted an independent study demonstrating that altered Notch3 protein degradation sustains Notch3-dependent leukemia via a differential localization/activity of the E3 ligase c-Cbl that in turn is regulated by the activity of the pre-TCR signaling. Overall, these findings unveiled novel properties of Notch3 receptor and suggested the use of deacetylase inhibitors for pharmacological treatment of human T-ALL.
Notch1; Glucocorticoids;	***2011- 2012.*** Later on, as an "assegnista di ricerca" at the Department of Molecular Medicine of University of Rome "Sapienza", Dr Palermo was involved in a study that helped to elucidate the key role of Notch1 signaling in the GC-resistance mechanisms by exploring the molecular basis underlying glucocorticoid (GC) resistance in T-ALL.

miRNAs; miR-223; Natural compounds; Chalcones; Notch inhibitors;	***2012 – 2018.*** At the end of 2012, he moved at the Center for Nanoscience Life @ Sapienza of the Fondazione Istituto Italiano di Tecnologia, where, as a Post Doc, by investigating the molecular mechanisms determining pathological perturbation of miRNAs expression and their target genes in cancer, revealed the oncogenic axis between Notch and miR-223 that, via repression of the onco-suppressor FBXW7, sustains the Notch tumor promoting program in T-ALL. This study also indicated that miR-223 is involved, in a Notch independent manner, in the mechanisms behind the T-ALL resistance to the inhibitors of gamma-secretase, thus suggesting novel therapy protocols targeting Notch/miR-223 axis. In addition, in collaboration with Prof. Bruno Botta of the Department of Chemistry and Technology of Drugs of Sapienza University of Rome and with Prof. Isabella Screpanti of the Department of Molecular Medicine of Sapienza University of Rome, Dr Palermo headed an independent research that has led to the identification of a novel chalcone derivative (named compound 8) endowed with Notch signaling inhibitory and anti-proliferative activity in T-ALL cell lines. Of note, chemical structure and application of this compound was included in a patent submission [Italian Patent Appl. (2016) N. 102016000132360] currently under international extension [*PCT International Appl.* (2017) PCT/ IB2017/058204].
Chalcone-derivatives; Gene regulation; Epigenetics;	***2018 – PRESENT.*** In 2018, Dr Palermo joined back the Department of Molecular Medicine of University of Rome "Sapienza" where, thanks to the financial support that he obtained from the MIUR and the "Sapienza" University of Rome and to the precious collaboration with the groups of Prof. Bruno Botta, of Dr. María Jesús Pérez Pérez from the Istituto de Química Médica del Consejo Superior de Investigaciones Científicas of Madrid and of Dr. Mattia Mori of the Department of Biotechnology, Chemistry and Pharmacy of the University of Siena, extended his study to additional classes of molecules with potential Notch-modulating activity in cancer. His work has led to the identification of chalcone-mimicking compounds as promising Notch-blocking and anti-cancer agents, and highlighted the demethylase JMJD3 as general Notch signaling co-activator in T-ALL. Of note, this last finding contributed to deciphering new mechanistic insights into the molecular processes governing Notch oncogenic activity in T-ALL and suggested JMJD3 enzymatic inhibition as a potential therapeutic target in T-ALL treatment. Accordingly, current Dr Palermo's research aims to investigate whether a similar epigenetic mechanism, specular to the one described in T-ALL, could regulate Notch activity in tumor contexts in which this signaling may act as a tumor suppressor, such as cervical cancer, squamous cell cancer, B-ALL and AML.

Part VII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	32	https://www.scopus.com	2005	2020
Books [scientific]	1	https://www.scopus.com	2018	

Total Impact factor	187,29
Total Citations	803
Average Citations per Product	24,33
Hirsch (H) index	17
Normalized H index*	1

*H index divided by the academic seniority (as time span from graduation).

.

Part VIII - Other Achievements

Year	Description
2016 - Present	Co-inventor of the Italian Patent Application (2016) n° 102016000132360 currently under international extension [PCT International Application (2017) n° PCT/ IB2017/058204]. Title: "Notch inhibitors for use in the treatment of T-cell acute lymphoblastic leukemia".

Part IX - Scientific Conferences

Year	Conference	Description
2013	RNA day - The centrality of non-coding RNA in gene regulation Sapienza Università di Rome.	Oral presentation. Title: Notch3 and NF-kB regulate the oncogenic role of miR-223 in T Cell Acute Lymphoblastic Leukemia.

Part X– Selected Publications for the evaluation

For each publication are reported: title, authors, reference data, journal IF (at the time of publication), citations, and press release (when available). Note: the database Scopus was used to calculate citations.

1. ***Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL.***
   L. Tottone, N. Zhdanovskaya, A. Carmona Pestana, M. Zampieri, F. Simeoni, S. Lazzari, V. Ruocco, M. Pelullo, P. Caiafa, M. P. Felli, S. Checquolo, D. Bellavia, C. Talora, I. Screpanti, **R. Palermo**.
   Frontiers in Oncology. **2019** Apr 3;9:198. DOCUMENT TYPE: Article.
   DOI: 10.3389/fonc.2019.00198. PMID: 31001470. PUBLISHER: Frontiers Media S.A.
   IF: 4,137. **Citations:** 7.

2. ***Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors in a Model of T-cell Acute Lymphoblastic Leukemia.***
   D. Quaglio, N. Zhdanovskaya, G. Tobajas, V. Cuartas, S. Balducci, M. S. Christodoulou, G. Fabrizi, M. Gargantilla, E. M. Priego, A. Carmona Pestana, D. Passarella, I. Screpanti, B. Botta, ***R. Palermo**, *M. Mori, *F. Ghirga, M. J. Perez-Perez.
   ACS Medicinal Chemistry Letters. **2019** Feb 26;10(4):639-643. DOCUMENT TYPE: Article.
   DOI: 10.1021/acsmedchemlett.8b00608. PMID: 30996810. PUBLISHER: American Chemical Society.
   IF: 3,737. **Citations:** 5. (***Co-Corresponding authors**)

3. ***Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.***
   M. Pelullo, F. Nardozza, S. Zema, R. Quaranta, C. Nicoletti, Z. M. Besharat, M. P. Felli, B. Cerbelli, G. d'Amati, **R. Palermo**, C. Capalbo, C. Talora, L. Di Marcotullio, G. Giannini, S. Checquolo, I. Screpanti, D. Bellavia.
   Cancer Research. **2019** Nov 1;79(21):5575-5586. DOCUMENT TYPE: Article.
   DOI: 10.1158/0008-5472.CAN-19-0145. PMID: 31506332. PUBLISHER: American Association for Cancer Research Inc.
   IF: 8,378. **Citations:** 1.

4. ***Natural Products Inspired Modulators of Cancer Stem Cells-specific Signaling.***
   R. Palermo, F. Ghirga, M. G. Piccioni, F. Bernardi, N. Zhdanovskaya, P. Infante, M. Mori.
   Current Pharmaceutical Design. **2018**;24(36):4251-4269. DOCUMENT TYPE: Review.
   DOI: 10.2174/1381612825666190111124822. PMID: 30636589. Publisher: Bentham Science Publishers
   IF: 2,412. **Citations:** 13.

5. ***NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.***
G. Diluvio, F. Del Gaudio, M. V. Giuli, G. Franciosa, E. Giuliani, **R. Palermo**, Z. M. Besharat, M. G. Pignataro, A. Vacca, G. d'Amati, M. Maroder, C. Talora, C. Capalbo, D. Bellavia, S. Checquolo,
Oncogenesis. **2018** May 25;7(5):42. DOCUMENT TYPE: Article.
DOI: 10.1038/s41389-018-0051-9. PMID: 29795369. PUBLISHER: Nature Publishing Group.
IF: 5,995. **Citations:** 15.

6. ***Notch signaling as a therapeutic target for acute lymphoblastic leukemia.***
*D. Bellavia, ***R. Palermo**, M. P. Felli, I. Screpanti, S. Checquolo.
Expert opinion on therapeutic targets. **2018** Apr;22(4):331-342. DOCUMENT TYPE: Review.
DOI: 10.1080/14728222.2018.1451840. PMID: 29527929. PUBLISHER: Taylor and Francis Ltd.
IF: 4,621. **Citations:** 13. (***Co-first authors**)

7. ***Identification of a novel chalcone derivative that inhibits Notch signaling in T-cell acute lymphoblastic leukemia.***
M. Mori, L. Tottone, D. Quaglio, N. Zhdanovskaya, C. Ingallina, M. Fusto, F. Ghirga, G. Peruzzi, M. E. Crestoni, F. Simeoni, F. Giulimondi, C. Talora, B. Botta, I. Screpanti, **R. Palermo**.
Scientific reports. **2017** May 19;7(1):2213. DOCUMENT TYPE: Article.
DOI: 10.1038/s41598-017-02316-9. PMID: 28526832. PUBLISHER: Nature Publishing Group.
IF: 4,122. **Citations:** 18.

8. ***Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression.***
G. Franciosa, G. Diluvio, F. D. Gaudio, M. V. Giuli, **R. Palermo**, P. Grazioli, A. F. Campese, C. Talora, D. Bellavia, G. D'Amati, Z. M. Besharat, C. Nicoletti, C. W. Siebel, L. Choy, A. Rustighi, G. D. Sal, I. Screpanti, S. Checquolo.
Oncogene. **2016** Sep 8;35(36):4741-51. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2016.5. PMID: 26876201. PUBLISHER: Nature Publishing Group.
IF: 7,519. **Citations:** 31.

9. ***Effect of Argania spinosa oil extract on proliferation and Notch1 and ERK1/2 signaling of T-cell acute lymphoblastic leukemia cell lines.***
B. Aribi, S. Zerizer, Z. Kabouche, I. Screpanti, **R. Palermo**.
Food and Agricultural Immunology. **2016** May 3;27(3):350-357. DOCUMENT TYPE: Article.
DOI: 10.1080/09540105.2015.1104654. PUBLISHER: Taylor and Francis Ltd.
IF: 1,392. **Citations:** 4.

10. ***The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.***
P. Vargas Romero, S. Cialfi, **R. Palermo**, C. De Blasio, S. Checquolo, D. Bellavia, S. Chiaretti, R. Foa, A. Amadori, A. Gulino, G. Zardo, C. Talora, I. Screpanti.
Leukemia. **2015** Dec;29(12):2442-5. DOCUMENT TYPE: Letter.
DOI: 10.1038/leu.2015.117. PMID: 25982911. PUBLISHER: Nature Publishing Group.
IF: 12.104. **Citations:** 20.

11. ***The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.***
M. Zampieri, F. Ciccarone, **R. Palermo**, S. Cialfi, C. Passananti, S. Chiaretti, D. Nocchia, C. Talora, I. Screpanti, P. Caiafa.
Biochimica et biophysica acta. **2014** Sep;1839(9):813-25. DOCUMENT TYPE: Article.
DOI: 10.1016/j.bbagrm.2014.06.017. PMID: 24984200. PUBLISHER: Elsevier Science BV.
IF: 6,332. **Citations:** 19.

12. ***Notch3/Jagged1 circuitry reinforces notch signaling and sustains T-ALL.***
M. Pelullo, R. Quaranta, C. Talora, S. Checquolo, S. Cialfi, M. P. Felli, G. te Kronnie, C. Borga, Z. M. Besharat, **R. Palermo**, L. Di Marcotullio, A. J. Capobianco, A. Gulino, I. Screpanti, D. Bellavia, *Neoplasia.* **2014** Dec;16(12):1007-17. DOCUMENT TYPE: Article.
DOI: 10.1016/j.neo.2014.10.004. PMID: 25499214. PUBLISHER: Elsevier Science INC.
IF: 4,252. **Citations:** 27.

13. ***The molecular basis of notch signaling regulation: a complex simplicity.***
R. Palermo, S. Checquolo, D. Bellavia, C. Talora, I. Screpanti.
Current molecular medicine. **2014** Jan;14(1):34-44. DOCUMENT TYPE: Review.
DOI: 10.2174/1566524013666131118105216. PMID: 24236458. PUBLISHER: Bentham Science Publishers B.V.
IF: 3,621. **Citations:** 28.

14. ***Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.***
*V. Kumar, ***R. Palermo**, C. Talora, A. F. Campese, S. Checquolo, D. Bellavia, L. Tottone, G. Testa, E. Miele, S. Indraccolo, A. Amadori, E. Ferretti, A. Gulino, A. Vacca, I. Screpanti.
Leukemia. **2014** Dec;28(12):2324-35. DOCUMENT TYPE: Article.
DOI: 10.1038/leu.2014.133. PMID: 24727676. PUBLISHER: Nature Publishing Group.
IF: 10,431. **Citations:** 100. (***Co-first authors**)

15. ***Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38alpha modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.***
A. Germani, A. Matrone, V. Grossi, A. Peserico, P. Sanese, M. Liuzzi, **R. Palermo**, S. Murzilli, A. F. Campese, G. Ingravallo, G. Canettieri, T. Tezil, C. Simone.
Cancer letters. **2014** Mar 1;344(1):110-118. DOCUMENT TYPE: Article.
DOI: 10.1016/j.canlet.2013.10.035. PMID: 24215867. PUBLISHER: Elsevier Ireland LTD.
IF: 5,621. **Citations:** 33.

16. ***Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis.***
S. Cialfi, **R. Palermo**, S. Manca, C. De Blasio, P. Vargas Romero, S. Checquolo, D. Bellavia, D. Uccelletti, M. Saliola, A. D'Alessandro, L. Zolla, A. Gulino, I. Screpanti, C. Talora.
Cell cycle. **2014**;13(13):2046-55. DOCUMENT TYPE: Article.
DOI: 10.4161/cc.29079. PMID: 24801890. PUBLISHER: Taylor and Francis Inc.
IF: 4,565. **Citations:** 17.

17. ***Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.***
*S. Cialfi, ***R. Palermo,** S. Manca, S. Checquolo, D. Bellavia, M. Pelullo, R. Quaranta, C. Dominici, A. Gulino, I. Screpanti, C. Talora.
Leukemia. **2013** Feb;27(2):485-8. DOCUMENT TYPE: Letter.
DOI: 10.1038/leu.2012.192. PMID: 22846929. PUBLISHER: Nature Publishing Group.
IF: 9,379. **Citations:** 20. (***Co-first authors**)

18. ***Acetylation controls Notch3 stability and function in T-cell leukemia.***
R. Palermo, S. Checquolo, A. Giovenco, P. Grazioli, V. Kumar, A. F. Campese, A. Giorgi, M. Napolitano, G. Canettieri, G. Ferrara, M. E. Schinina, M. Maroder, L. Frati, A. Gulino, A. Vacca, I. Screpanti.
Oncogene. **2012** Aug 16;31(33):3807-17. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2011.533. PMID: 22120716. PUBLISHER: Nature Publishing Group.
IF: 7,357. **Citations:** 37.

19. ***Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease.***
M. Napolitano, L. Costa, **R. Palermo**, A. Giovenco, A. Vacca, A. Gulino.
Brain Research Bulletin. **2011** May 30;85(3-4):231-7. DOCUMENT TYPE: Article.
DOI: 10.1016/j.brainresbull.2011.03.011. PMID: 21440606. PUBLISHER: Pergamon Elsevier Science.
IF: 2,818. **Citations:** 29.

20. ***Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia.***
*S. Checquolo, ***R. Palermo**, S. Cialfi, G. Ferrara, C. Oliviero, C. Talora, D. Bellavia, A. Giovenco, P. Grazioli, L. Frati, A. Gulino, I. Screpanti.
Oncogene. **2010** Mar 11;29(10):1463-74. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2009.446. PMID: 19966856. PUBLISHER: Nature Publishing Group.
IF: 7,414. **Citations:** 20. **(*Co-first authors)**

Part XI - Complete list of Publications

For each publication are reported: title, authors, reference data, journal IF (at the time of publication), citations, and press release (when available). Note: the database Scopus was used to calculate citations.

1. ***DNA Damage Stress: Cui Prodest?***
N. Verma, M. Franchitto, A. Zonfrilli, S. Cialfi, **R. Palermo**, C. Talora.
International Journal of Molecular Sciences. **2019** Mar 1;20(5). DOCUMENT TYPE: Review.
DOI: 10.3390/ijms20051073. PMID: 30832234. PUBLISHER: MDPI.
IF: 4,183. **Citations:** 6.

2. ***Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL.***
L. Tottone, N. Zhdanovskaya, A. Carmona Pestana, M. Zampieri, F. Simeoni, S. Lazzari, V. Ruocco, M. Pelullo, P. Caiafa, M. P. Felli, S. Checquolo, D. Bellavia, C. Talora, I. Screpanti, **R. Palermo**.
Frontiers in Oncology. **2019** Apr 3;9:198. DOCUMENT TYPE: Article.
DOI: 10.3389/fonc.2019.00198. PMID: 31001470. PUBLISHER: Frontiers Media S.A.
IF: 4,137. **Citations:** 7.

3. ***Chalcones and Chalcone-mimetic Derivatives as Notch Inhibitors in a Model of T-cell Acute Lymphoblastic Leukemia.***
D. Quaglio, N. Zhdanovskaya, G. Tobajas, V. Cuartas, S. Balducci, M. S. Christodoulou, G. Fabrizi, M. Gargantilla, E. M. Priego, A. Carmona Pestana, D. Passarella, I. Screpanti, B. Botta, ***R. Palermo**, *M. Mori, *F. Ghirga, M. J. Perez-Perez.
ACS Medicinal Chemistry Letters. **2019** Feb 26;10(4):639-643. DOCUMENT TYPE: Article.
DOI: 10.1021/acsmedchemlett.8b00608. PMID: 30996810. PUBLISHER: American Chemical Society.
IF: 3,737. **Citations:** 5. **(*Co-Corresponding authors)**

4. ***Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.***
M. Pelullo, F. Nardozza, S. Zema, R. Quaranta, C. Nicoletti, Z. M. Besharat, M. P. Felli, B. Cerbelli, G. d'Amati, **R. Palermo**, C. Capalbo, C. Talora, L. Di Marcotullio, G. Giannini, S. Checquolo, I. Screpanti, D. Bellavia.
Cancer Research. **2019** Nov 1;79(21):5575-5586. DOCUMENT TYPE: Article.
DOI: 10.1158/0008-5472.CAN-19-0145. PMID: 31506332. PUBLISHER: American Association for Cancer Research Inc.
IF: 8,378. **Citations:** 1.

5. ***PLK1 targets NOTCH1 during DNA damage and mitotic progression.***
C. De Blasio, A. Zonfrilli, M. Franchitto, G. Mariano, S. Cialfi, N. Verma, S. Checquolo, D. Bellavia, **R. Palermo**, D. Benelli, I. Screpanti, C. Talora.
The Journal of biological chemistry. **2019** Nov 22;294(47):17941-17950. DOCUMENT TYPE: Article.
DOI: 10.1074/jbc.RA119.009881. PMID: 31597699. PUBLISHER: American Society for Biochemistry and Molecular Biology Inc.
IF: 4,106. **Citations:** 1.

6. ***Natural Products Inspired Modulators of Cancer Stem Cells-specific Signaling.***
R. Palermo, F. Ghirga, M. G. Piccioni, F. Bernardi, N. Zhdanovskaya, P. Infante, M. Mori.
Current Pharmaceutical Design. **2018**;24(36):4251-4269. DOCUMENT TYPE: Review.
DOI: 10.2174/1381612825666190111124822. PMID: 30636589. Publisher: Bentham Science Publishers B.V.
IF: 2,412. **Citations:** 13.

7. ***NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.***
G. Diluvio, F. Del Gaudio, M. V. Giuli, G. Franciosa, E. Giuliani, **R. Palermo**, Z. M. Besharat, M. G. Pignataro, A. Vacca, G. d'Amati, M. Maroder, C. Talora, C. Capalbo, D. Bellavia, S. Checquolo,
Oncogenesis. **2018** May 25;7(5):42. DOCUMENT TYPE: Article.
DOI: 10.1038/s41389-018-0051-9. PMID: 29795369. PUBLISHER: Nature Publishing Group.
IF: 5,995. **Citations:** 15.

8. ***Notch signaling as a therapeutic target for acute lymphoblastic leukemia.***
*D. Bellavia, ***R. Palermo**, M. P. Felli, I. Screpanti, S. Checquolo.
Expert opinion on therapeutic targets. **2018** Apr;22(4):331-342. DOCUMENT TYPE: Review.
DOI: 10.1080/14728222.2018.1451840. PMID: 29527929. PUBLISHER: Taylor and Francis Ltd.
IF: 4,621. **Citations:** 13. (***Co-first authors**)

9. ***The Notch3 Receptor and Its Intracellular Signaling-Dependent Oncogenic Mechanisms.***
D. Bellavia, S. Checquolo, **R. Palermo**, I. Screpanti.
Advances in experimental medicine and biology. **2018**;1066:205-222. DOCUMENT TYPE: Book Chapter.
DOI: 10.1007/978-3-319-89512-3_10. PMID: 30030828. PUBLISHER: Springer New York LLC.
IF: 2,126. **Citations:** 2.

10. ***Maml1 acts cooperatively with Gli proteins to regulate sonic hedgehog signaling pathway.***
R. Quaranta, M. Pelullo, S. Zema, F. Nardozza, S. Checquolo, D. M. Lauer, F. Bufalieri, **R. Palermo**, M. P. Felli, A. Vacca, C. Talora, L. Di Marcotullio, I. Screpanti, D. Bellavia.
Cell death & disease. **2017** Jul 20;8(7):e2942. DOCUMENT TYPE: Article.
DOI: 10.1038/cddis.2017.326. PMID: 28726779. PUBLISHER: Nature Publishing Group.
IF: 5,638. **Citations:** 11.

11. ***Manipulation of lipoplex concentration at the cell surface boosts transfection efficiency in hard-to transfect cells.***
S. Palchetti, D. Pozzi, C. Marchini, A. Amici, C. Andreani, C. Bartolacci, L. Digiacomo, V. Gambini, F. Cardarelli, C. Di Rienzo, G. Peruzzi, H. Amenitsch, **R. Palermo**, I. Screpanti, G. Caracciolo.
Nanomedicine: Nanotechnology, Biology, and Medicine. **2017** Feb;13(2):681-691. DOCUMENT TYPE: Article.
DOI: 10.1016/j.nano.2016.08.019. PMID: 27565691. PUBLISHER: Elsevier Inc.
IF: 6,500. **Citations:** 14.

12. ***Identification of a novel chalcone derivative that inhibits Notch signaling in T-cell acute lymphoblastic leukemia.***
M. Mori, L. Tottone, D. Quaglio, N. Zhdanovskaya, C. Ingallina, M. Fusto, F. Ghirga, G. Peruzzi, M. E. Crestoni, F. Simeoni, F. Giulimondi, C. Talora, B. Botta, I. Screpanti, **R. Palermo**.
Scientific reports. **2017** May 19;7(1):2213. DOCUMENT TYPE: Article.
DOI: 10.1038/s41598-017-02316-9. PMID: 28526832. PUBLISHER: Nature Publishing Group.
IF: 4,122. **Citations:** 18.

13. ***Regulation of proapoptotic proteins Bak1 and p53 by miR-125b in an experimental model of Alzheimer's disease: Protective role of 17beta-estradiol.***
F. Micheli, **R. Palermo**, C. Talora, E. Ferretti, A. Vacca, M. Napolitano.
Neuroscience letters. **2016** Aug 26;629:234-240. DOCUMENT TYPE: Article.
DOI: 10.1016/j.neulet.2016.05.049. PMID: 27235580. PUBLISHER: Elsevier Ireland Ltd.
IF: 2,180. **Citations:** 17.

14. ***Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression.***
G. Franciosa, G. Diluvio, F. D. Gaudio, M. V. Giuli, **R. Palermo**, P. Grazioli, A. F. Campese, C. Talora, D. Bellavia, G. D'Amati, Z. M. Besharat, C. Nicoletti, C. W. Siebel, L. Choy, A. Rustighi, G. D. Sal, I. Screpanti, S. Checquolo.
Oncogene. **2016** Sep 8;35(36):4741-51. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2016.5. PMID: 26876201. PUBLISHER: Nature Publishing Group.
IF: 7,519. **Citations:** 31.

15. ***Effect of Argania spinosa oil extract on proliferation and Notch1 and ERK1/2 signaling of T-cell acute lymphoblastic leukemia cell lines.***
B. Aribi, S. Zerizer, Z. Kabouche, I. Screpanti, **R. Palermo**.
Food and Agricultural Immunology. **2016** May 3;27(3):350-357. DOCUMENT TYPE: Article.
DOI: 10.1080/09540105.2015.1104654. PUBLISHER: Taylor and Francis Ltd.
IF: 1,392. **Citations:** 4.

16. ***The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey-Hailey disease.***
S. Cialfi, L. Le Pera, C. De Blasio, G. Mariano, **R. Palermo**, A. Zonfrilli, D. Uccelletti, C. Palleschi, G. Biolcati, L. Barbieri, I. Screpanti, C. Talora.
Scientific reports. **2016** Aug 16;6:31567. DOCUMENT TYPE: Article.
DOI: 10.1038/srep31567. PMID: 27528123. PUBLISHER:Nature Publishing Group.
IF: 4,259. **Citations:** 8.

17. ***The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.***
P. Vargas Romero, S. Cialfi, **R. Palermo**, C. De Blasio, S. Checquolo, D. Bellavia, S. Chiaretti, R. Foa, A. Amadori, A. Gulino, G. Zardo, C. Talora, I. Screpanti.
Leukemia. **2015** Dec;29(12):2442-5. DOCUMENT TYPE: Letter.
DOI: 10.1038/leu.2015.117. PMID: 25982911. PUBLISHER: Nature Publishing Group.
IF: 12.104. **Citations:** 20.

18. ***The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.***
M. Zampieri, F. Ciccarone, **R. Palermo**, S. Cialfi, C. Passananti, S. Chiaretti, D. Nocchia, C. Talora, I. Screpanti, P. Caiafa.
Biochimica et biophysica acta. **2014** Sep;1839(9):813-25. DOCUMENT TYPE: Article.
DOI: 10.1016/j.bbagrm.2014.06.017. PMID: 24984200. PUBLISHER: Elsevier.
IF: 6,332. **Citations:** 19.

19. ***Notch3/Jagged1 circuitry reinforces notch signaling and sustains T-ALL.***
M. Pelullo, R. Quaranta, C. Talora, S. Checquolo, S. Cialfi, M. P. Felli, G. te Kronnie, C. Borga, Z. M. Besharat, **R. Palermo**, L. Di Marcotullio, A. J. Capobianco, A. Gulino, I. Screpanti, D. Bellavia,
Neoplasia. **2014** Dec;16(12):1007-17. DOCUMENT TYPE: Article.
DOI: 10.1016/j.neo.2014.10.004. PMID: 25499214. PUBLISHER: Elsevier Inc.
IF: 4,252. **Citations:** 27.

20. ***The molecular basis of notch signaling regulation: a complex simplicity.***
R. Palermo, S. Checquolo, D. Bellavia, C. Talora, I. Screpanti.
Current molecular medicine. **2014** Jan;14(1):34-44. DOCUMENT TYPE: Review.
DOI: 10.2174/1566524013666131118105216. PMID: 24236458. PUBLISHER: Bentham Science Publishers B.V.
IF: 3,621. **Citations:** 28.

21. ***Numb-dependent integration of pre-TCR and p53 function in T-cell precursor development.***
N. M. Martin-Blanco, S. Checquolo, F. Del Gaudio, **R. Palermo**, G. Franciosa, L. Di Marcotullio, A. Gulino, M. Canelles, I. Screpanti.
Cell death & disease. **2014** Oct 16;5:e1472. DOCUMENT TYPE: Article.
DOI: 10.1038/cddis.2014.438. PMID: 25321479. PUBLISHER: Nature Publishing Group.
IF: 5,014. **Citations:** 4.

22. ***Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.***
*V. Kumar, ***R. Palermo**, C. Talora, A. F. Campese, S. Checquolo, D. Bellavia, L. Tottone, G. Testa, E. Miele, S. Indraccolo, A. Amadori, E. Ferretti, A. Gulino, A. Vacca, I. Screpanti.
Leukemia. **2014** Dec;28(12):2324-35. DOCUMENT TYPE: Article.
DOI: 10.1038/leu.2014.133. PMID: 24727676. PUBLISHER: Nature Publishing Group.
IF: 10,431. **Citations:** 100. (***Co-first authors**)

23. ***Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38alpha modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.***
A. Germani, A. Matrone, V. Grossi, A. Peserico, P. Sanese, M. Liuzzi, **R. Palermo**, S. Murzilli, A. F. Campese, G. Ingravallo, G. Canettieri, T. Tezil, C. Simone.
Cancer letters. **2014** Mar 1;344(1):110-118. DOCUMENT TYPE: Article.
DOI: 10.1016/j.canlet.2013.10.035. PMID: 24215867. PUBLISHER: Elsevier IRELAND LTD.
IF: 5,621. **Citations:** 33.

24. ***Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis.***
S. Cialfi, **R. Palermo**, S. Manca, C. De Blasio, P. Vargas Romero, S. Checquolo, D. Bellavia, D. Uccelletti, M. Saliola, A. D'Alessandro, L. Zolla, A. Gulino, I. Screpanti, C. Talora.
Cell cycle. **2014**;13(13):2046-55. DOCUMENT TYPE: Article.
DOI: 10.4161/cc.29079. PMID: 24801890. PUBLISHER: Taylor and Francis Inc.
IF: 4,565. **Citations:** 17.

25. ***Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.***
*S. Cialfi, ***R. Palermo,** S. Manca, S. Checquolo, D. Bellavia, M. Pelullo, R. Quaranta, C. Dominici, A. Gulino, I. Screpanti, C. Talora.
Leukemia. **2013** Feb;27(2):485-8. DOCUMENT TYPE: Letter.
DOI: 10.1038/leu.2012.192. PMID: 22846929. PUBLISHER: Nature Publishing Group.
IF: 9,379. **Citations:** 20. (***Co-first authors**)

26. ***Acetylation controls Notch3 stability and function in T-cell leukemia.***
R. Palermo, S. Checquolo, A. Giovenco, P. Grazioli, V. Kumar, A. F. Campese, A. Giorgi, M. Napolitano, G. Canettieri, G. Ferrara, M. E. Schinina, M. Maroder, L. Frati, A. Gulino, A. Vacca, I. Screpanti.
Oncogene. **2012** Aug 16;31(33):3807-17. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2011.533. PMID: 22120716. PUBLISHER: Nature Publishing Group.
IF: 7,357. **Citations:** 37.

27. ***Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease.***
M. Napolitano, L. Costa, **R. Palermo**, A. Giovenco, A. Vacca, A. Gulino.
Brain research bulletin. **2011** May 30;85(3-4):231-7. DOCUMENT TYPE: Article.
DOI: 10.1016/j.brainresbull.2011.03.011. PMID: 21440606. PUBLISHER: Pergamon Elsevier Science.
IF: 2,818. **Citations:** 29.

28. ***Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia.***
*S. Checquolo, ***R. Palermo**, S. Cialfi, G. Ferrara, C. Oliviero, C. Talora, D. Bellavia, A. Giovenco, P. Grazioli, L. Frati, A. Gulino, I. Screpanti.
Oncogene. **2010** Mar 11;29(10):1463-74. DOCUMENT TYPE: Article.
DOI: 10.1038/onc.2009.446. PMID: 19966856. PUBLISHER: Nature Publishing Group.
IF: 7,414. **Citations:** 20. **(*Co-first authors)**

29. ***NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease.***
M. Napolitano, D. Zei, D. Centonze, **R. Palermo**, G. Bernardi, A. Vacca, P. Calabresi, A. Gulino.
Neuroscience letters. **2008** Apr 4;434(3):241-6. DOCUMENT TYPE: Article.
DOI: 10.1016/j.neulet.2007.09.056. PMID: 18329171. PUBLISHER: Elsevier IRELAND LTD.
IF: 2,200. **Citations:** 26.

30. ***Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia.***
A. Vacca, M. P. Felli, **R. Palermo**, G. Di Mario, A. Calce, M. Di Giovine, L. Frati, A. Gulino, I. Screpanti.
The EMBO journal. **2006** Mar 8;25(5):1000-8. DOCUMENT TYPE: Article.
DOI: 10.1038/sj.emboj.7600996. PMID: 16498412. PUBLISHER: EMBO Press.
IF: 10,086. **Citations:** 101.

31. ***Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis.***
C. Talora, S. Cialfi, C. Oliviero, **R. Palermo**, M. Pascucci, L. Frati, A. Vacca, A. Gulino, I. Screpanti.
Blood. **2006** Apr 15;107(8):3313-20. DOCUMENT TYPE: Article.
DOI: 10.1182/blood-2005-07-2823. PMID: 16368887. PUBLISHER:American Society of Hematology.
IF: 10,370. **Citations:** 35.

32. ***The archaeal eIF2 homologue: functional properties of an ancient translation initiation factor.***
N. Pedulla, **R. Palermo**, D. Hasenohrl, U. Blasi, P. Cammarano, P. Londei.
Nucleic acids research. **2005** Mar 23;33(6):1804-12. DOCUMENT TYPE: Article.
DOI: 10.1093/nar/gki321. PMID: 15788752. PUBLISHER: Oxford University Press.
IF: 7,552. **Citations:** 59.

33. ***PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia.***
M. P. Felli, A. Vacca, A. Calce, D. Bellavia, A. F. Campese, R. Grillo, M. Di Giovine, S. Checquolo, C. Talora, **R. Palermo**, G. Di Mario, L. Frati, A. Gulino, I. Screpanti.
Oncogene. **2005** Feb 3;24(6):992-1000. DOCUMENT TYPE: Article.
DOI: 10.1038/sj.onc.1208302. PMID: 15592506. PUBLISHER: Nature Publishing Group.
IF: 6,872. **Citations:** 62.

Rome, 15/06/2020

Signature

Rosa Palermo